
Opinion|Videos|February 6, 2025
Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies
Panelists explore how the introduction of tyrosine kinase inhibitors (TKIs) could affect the perceived benefits of the port delivery system, as these agents may offer an alternative approach to reducing injection burden while potentially providing broader therapeutic effects.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- If TKIs become available, how would this impact the relative benefits of PDS?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
From AI to injury patterns: Insights from emerging ophthalmic research
2
FLORetina 2025: Reframing retinal disease through the lens of choroidal health
3
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
4
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
5












































